Trivarx Stalls at 1¢: Why the Medical-Tech Stock Is Facing Deep Valuation and Liquidity Woes
Trivarx’s AUD 0.01 stock flat‑lined amid market stagnation, raising doubts about its medical‑tech claims and exposing liquidity and valuation risks for investors.
3 minutes to read